Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNAMIC: Neoadjuvant Atezolizumab + Bevacizumab in HCC
NCT04954339Phase 2Completed
- Start
- Oct 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC). Started Oct 2021; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04954339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954339.